[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vte-venous-thromboembolism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vte-venous-thromboembolism":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,50,81,112,139,174,204,226,248],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100635973","the-oat-trail-the-obesity-anti-coagulation-thromboprophylaxis-trial-100635973",false,"NCT07559643","The OAT Trail: The Obesity Anti-Coagulation Thromboprophylaxis Trial.","A Prospective, Randomised Controlled Trial Comparing Weight-based Tinzaparin Versus Weight-based Enoxaparin for Peri-operative Thromboprophylaxis in Patients Undergoing Bariatric Surgery: Evaluation of Anti-Xa Levels and Clinical Outcomes.","The OAT-RCT","Inclusion Criteria:\n\n* Age ≥18 years\n* BMI ≥40 kg\u002Fm², or BMI ≥35 kg\u002Fm² with at least one obesity-related comorbidity (type 2 diabetes, hypertension, obstructive sleep apnoea, dyslipidaemia, or metabolic dysfunction-associated steatotic liver disease (MASLD))\n* Scheduled to undergo laparoscopic bariatric surgery (sleeve gastrectomy or gastric bypass) at St Vincent's University Hospital, Dublin, Ireland\n* Capacity to provide written informed consent\n\nExclusion Criteria:\n\n* Current therapeutic anticoagulation for any indication Known allergy or hypersensitivity to tinzaparin, enoxaparin, heparin, or any heparin-derived product, including documented heparin-induced thrombocytopaenia (HIT) Any other contraindication to LMWH therapy Severe renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²) Known haematological disorder or coagulopathy Pregnancy, breastfeeding, or planning pregnancy during the study period Active major bleeding or high bleeding risk at the discretion of the treating clinician Inability to provide written informed consent Participation in another interventional clinical study within 30 days prior to enrolment","ALL","18 Years",{"count":20,"type":21},180,"ESTIMATED","INTERVENTIONAL",[24],"NA","Blood clots in the legs or lungs (called venous thromboembolism or VTE) are one of the most serious complications after weight loss surgery. Most blood clots occur after patients go home from hospital, within the first 30 days after surgery. To prevent blood clots, all patients having weight loss surgery receive a daily blood-thinning injection for 21 days after their operation.\n\nTwo blood-thinning injections are currently used at St Vincent's University Hospital for this purpose: enoxaparin (Clexane®) and tinzaparin (Innohep®). Both belong to a group of medicines called low molecular weight heparins (LMWHs). Patients with obesity process these medicines differently to the general population, and previous studies from our hospital have shown that fewer than 53% of patients achieve adequate blood-thinning levels with either injection when measured by a blood test called an anti-Xa level.\n\nPatients will be randomly assigned (like a coin toss) to receive either tinzaparin or enoxaparin for 21 days after their surgery. Both injections are already in routine use at this hospital. A single extra blood sample will be taken on the second day after surgery to measure the anti-Xa level, which tells us whether the injection is providing adequate protection against blood clots. This blood sample will be taken at the same time as routine post-operative blood tests so that no additional blood draws are required.\n\nThe study will also look at rates of blood clots and bleeding events within 30 days of surgery, and will ask patients to complete a short questionnaire at their six-week follow-up appointment about their experience with the injection.",[27,28,29,30],"Bariatric Surgery","Anti-Xa Activity","VTE (Venous Thromboembolism)","Obesity & Overweight",[32,33,34,35,36],"Anti-Xa","Metabolic Bariatric Surgery","Obesity","VTE","DVT","NOT_YET_RECRUITING","2026-05-14",{"date":40,"type":41},"2026-05-18","ACTUAL",{"date":43,"type":21},"2026-08-01",{"date":45,"type":21},"2026-12-01",{"name":47,"class":48},"University College Dublin","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":79,"locationsCount":49},"100629533","venous-thromboembolism-and-chronic-pain-after-major-limb-trauma-100629533","NCT07475910","Venous Thromboembolism and Chronic Pain After Major Limb Trauma","Venous Thromboembolism and Chronic Pain After Major Limb Trauma: A Prospective Cohort Study","THROMBO-PAIN","Inclusion Criteria:\n\n* Age ≥18 years\n* Major upper or lower limb trauma\n* Surgical treatment and\u002For immobilization ≥72 hours\n* Enrollment within 72 hours of admission\n* Informed consent\n\nExclusion Criteria:\n\n* Pre-existing chronic pain unrelated to trauma (investigator judgment)\n* Therapeutic anticoagulation prior to trauma\n* Cognitive inability to complete follow-up\n* Expected survival \\\u003C48 hours","60 Years",{"count":60,"type":21},150,"OBSERVATIONAL","Major limb trauma is associated with a high risk of venous thromboembolism (VTE) due to systemic inflammation, endothelial injury, immobilization, and hypercoagulability. While VTE is commonly studied as a short-term complication affecting morbidity and mortality, its potential relationship with long-term pain outcomes after trauma has not been well investigated.\n\nThis prospective observational cohort study aims to evaluate whether objectively confirmed VTE is associated with an increased risk of persistent clinically significant pain after major limb trauma. Adult patients with severe upper or lower limb injuries requiring surgical treatment or prolonged immobilization will be enrolled within 72 hours of hospital admission and followed for six months.\n\nThe study will assess whether patients who develop VTE have a higher likelihood of persistent pain compared with those without VTE. In addition, the study will explore the association between baseline VTE risk (using the Trauma Embolic Scoring System, TESS), thromboprophylaxis timing, and long-term pain outcomes. Secondary analyses will evaluate neuropathic pain symptoms, pain interference with daily activities, quality of life, opioid consumption, and functional recovery.\n\nUnderstanding the relationship between thromboembolic complications and persistent pain may help improve risk stratification, optimize thromboprophylaxis strategies, and support early rehabilitation planning in patients with major limb trauma.",[29,64,65,66],"Phantom Limb Pain After Amputation","Chronic Pain","Chronic Pain Due to Injury",[68,69,70,71,72],"Venous thromboembolism","Post-traumatic chronic pain","Neuropathic pain","Major limb trauma","Trauma Embolic Scoring System (TESS)","2026-03-16",{"date":75,"type":41},"2026-03-18",{"date":77,"type":21},"2026-03-15",{"date":77,"type":21},{"name":80,"class":48},"Charitable Organisation Charitable Fund Superhumans (Co Cf Superhumans)",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":93,"conditions":94,"keywords":98,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":49},"100629041","phase-4-a-clinical-trial-on-the-outcomes-of-comprehensive-enhanced-prophylaxis-management-cepm-in-chinese-patients-with-egfr-mutated-advanced-nsclc-receiving-amivantamab-based-regimens-100629041","NCT07469488","A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens","AmiCARE: A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens","AmiCARE","Inclusion Criteria:\n\n* Aged at least 18 (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of informed consent.\n* Participants have a confirmed diagnosis of locally advanced or metastatic EGFR-mutated NSCLC (Stage IIIB\u002FC or IV).\n* Participant \\[and\u002For their legally authorized representative where applicable\\] must sign an ICF allowing source data verification in accordance with local requirements and indicating that the participant understands the purpose of and procedures required for the study and is willing to participate in the study.\n* Participants have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1.\n* Participants with asymptomatic or previously treated and stable brain metastases may participate in this study. Participants who have completed definitive therapy, are not on steroids, and have a stable clinical status for at least 2 weeks prior to study treatment are allowed.\n* Be eligible for, and agree to comply with, the use of enhanced dermatologic management and enhanced IRR prophylaxis management during the duration of anticancer treatments with amivantamab and lazertinib, or amivantamab with chemotherapy.\n\nCohort 1 (cEGFR 1L):\n\n* EGFR mutation must be an Ex19del or Ex21 L858R substitution.\n* Participants who plan to receive Amivantamab (IV form) and Lazertinib regimen treatment based on physician's medical judgement.\n* Participant is treatment-naive and not amenable to curative therapy including surgical resection or (chemo)radiation. Adjuvant or neoadjuvant therapy is allowed if last dose administered more than 12 months prior to the development of locally advanced or metastatic disease.\n* Be eligible for, and agree to comply with, the use of prophylactic-dose anticoagulation with a direct oral anticoagulant or a low molecular weight heparin during the first 4 months of anticancer treatment (from Day 1-120) according to Chinese Society of Clinical Oncology (CSCO) guidelines.\n\nCohort 2 (cEGFR 2L):\n\n* EGFR mutation must be an Ex19del or Ex21 L858R substitution.\n* Participants who plan to receive Amivantamab (IV form) and Chemotherapy regimen treatment based on physician's medical judgement.\n* Participants must have progressed on or after prior therapy including an EGFR TKI for advanced or metastatic NSCLC. Amivantamab and chemotherapy will be received as a second-line treatment.\n\nCohort 3 (EGFR Ex20ins 1L):\n\n* EGFR mutation must be an EGFR Ex20ins.\n* Participants who plan to receive Amivantamab (IV form) and Chemotherapy regimen treatment based on physician's medical judgement.\n* Participant is treatment-naive and not amenable to curative therapy including surgical resection or (chemo)radiation. Adjuvant or neoadjuvant therapy for is allowed if last dose administered more than 12 months prior to the development of locally advanced or metastatic disease.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding.\n* Is currently enrolled in an interventional clinical study.\n* Any condition for which, at the investigator's discretion, participation would not be in the best interest of the participant (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.",{"count":90,"type":21},122,[92],"PHASE4","This study aims to explore the clinical outcomes of Comprehensive Enhanced Preventive Management (CEPM) combined with an amivantamab-containing treatment regimen in Chinese patients with EGFR-mutated advanced NSCLC.",[95,29,96,97],"NSCLC (Advanced Non-small Cell Lung Cancer)","Rash Due to Epidermal Growth Factor Receptor Inhibitors","Infusion Reaction",[99,100,101,102],"Amivantamab","Lazertinib","NSCLC","EGFR","2026-03-09",{"date":105,"type":41},"2026-03-13",{"date":107,"type":21},"2026-04-30",{"date":109,"type":21},"2029-12-31",{"name":111,"class":48},"Shanghai Pulmonary Hospital, Shanghai, China",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":49},"100593329","phase-3-doac---dosing-options-in-anticoagulation-prophylaxis-100593329","NCT07005024","DOAC - Dosing Options in AntiCoagulation Prophylaxis","A Comparison of Anticoagulant Dosing Strategies to Reduce VTE and Mortality in Cancer Outpatients: A Randomized, Pragmatic Trial","DOAC","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosed with an active solid tumor or lymphoma\n* Starting a new systemic cancer treatment or changing cancer treatment\n* Khorana Risk Score of 2 (calculated based on lab and clinical data at treatment initiation)\n* Not currently receiving therapeutic anticoagulation\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Active bleeding or high risk of bleeding (e.g., recent major surgery, CNS tumors with hemorrhagic risk)\n* Known contraindication to apixaban (e.g., allergy, severe liver disease, dual strong CYP3A4 and P-gp inhibitors)\n* Current therapeutic-dose anticoagulation for VTE or atrial fibrillation\n* Platelet count \\\u003C 50,000\u002FµL\n* Creatinine clearance \\\u003C 25 mL\u002Fmin\n* Life expectancy \\\u003C 3 months\n* Pregnant or breastfeeding\n* Inability to comply with study procedures",{"count":121,"type":21},996,[123],"PHASE3","Blood clots, also known as venous thromboembolism (VTE), are a common and serious complication for people with cancer. They can lead to pain, hospitalizations, delayed cancer treatment, and even death. Although national guidelines recommend using blood thinners (anticoagulants) to prevent clots in cancer patients who are at higher risk, these medications are not commonly prescribed due to concerns about bleeding and inconvenience.\n\nThis study will test different ways of using a commonly prescribed blood thinner called apixaban (brand name Eliquis) to see if it can safely and effectively reduce the risk of blood clots and death in cancer patients who are at moderate risk for VTE. The study focuses on people who have a \"Khorana score\" of 2, which puts them at intermediate risk for developing blood clots.\n\nThe study will include approximately 996 participants with solid tumors or lymphoma who are starting or recently started cancer-directed therapy. Participants will be randomly assigned to one of three groups:\n\nGroup 1: Apixaban 2.5 mg twice a day (standard prophylactic dose)\n\nGroup 2: Apixaban 5 mg once a day (an alternative, more convenient dose)\n\nGroup 3: No anticoagulant (standard care)\n\nParticipants will take the assigned treatment (if applicable) for 6 months. Researchers will monitor whether participants develop blood clots, experience serious bleeding events, or die from any cause during the study period.\n\nBy comparing these three groups, the researchers hope to learn whether a once-daily dose of apixaban can work as well as the standard twice-daily dose, and whether either dosing strategy is better than no anticoagulation at all. If successful, the study may help increase the safe use of VTE prevention in cancer patients and improve overall outcomes, especially in patients at intermediate risk.\n\nThis is a pragmatic trial, meaning it is designed to fit into real-world clinical practice with minimal extra procedures. The study drug is not provided by the sponsor and will be prescribed and filled through usual care channels. Participants and their doctors will decide whether to continue the medication after the study ends.",[126,29],"Cancer",[128],"Apixaban","RECRUITING","2026-02-02",{"date":132,"type":41},"2026-02-05",{"date":134,"type":41},"2025-10-17",{"date":136,"type":21},"2035-08",{"name":138,"class":48},"University of Vermont",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":22,"phases":149,"briefSummary":150,"conditions":151,"keywords":158,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":49},"100613720","reduced-dose-apixaban-and-rivaroxaban-versus-low-molecular-weight-heparin-in-patients-with-hematologic-malignancies-100613720","NCT07270263","Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies","Efficacy and Safety of Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies: A Prospective Randomized Study","HEM-DOAC","Inclusion Criteria:\n\n* Active hematologic malignancy at the time of initiation of systemic therapy, including multiple myeloma, myeloproliferative neoplasm, lymphoma or other hematologic cancer with a Khorana score ≥ 2 points (intermediate or high risk of venous thromboembolism, VTE)\n* Use of anticoagulant agents for primary thromboprophylaxis, including direct oral anticoagulants (DOACs) at reduced doses (apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily) or low-molecular-weight heparin (LMWH) (enoxaparin 40 mg subcutaneously once daily).\n\nExclusion Criteria:\n\n* Major bleeding within the last month (including gastrointestinal or intracranial bleeding).\n* Active major bleeding.\n* Hemoglobin concentration \\\u003C 8 g\u002FdL.\n* Thrombocytopenia with platelet count \\\u003C30 × 10⁹\u002FL.\n* ECOG performance status of 3 or 4.\n* Expected survival \\\u003C6 months.\n* History of mechanical heart valve or severe mitral stenosis.\n* Estimated glomerular filtration rate (eGFR) \\\u003C 25 mL\u002Fmin.\n* Hepatic impairment (ALT ≥ 3× upper limit of normal or bilirubin ≥ 2× upper limit of normal).\n* Acute coronary syndrome or ischemic stroke within the last 6 months.\n* Anticipated significant drug-drug interactions between DOACs and anticancer agents.\n* Known antiphospholipid syndrome (APS).",{"count":148,"type":21},100,[24],"This study investigates the efficacy and safety of direct oral anticoagulants (DOACs) in comparison with standard low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in patients with hematological malignancies. Eligible participants will be randomized to receive reduced-dose apixaban, reduced-dose rivaroxaban, or standard-dose LMWH. The primary objective is to evaluate the incidence of venous thromboembolism during a 6-month follow-up period. Secondary objectives include assessment of bleeding complications, overall survival, and treatment adherence. The results of this study may provide evidence for safer and more convenient thromboprophylaxis strategies in patients with blood cancers.",[152,153,154,155,29,156,157],"Lymphoma","Leukemia","Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma","Venous Thromboembolic Disease","PE - Pulmonary Embolism","Hematologic Malignacies",[128,159,160,161,162,163,164],"Rivaroxaban","Low-Molecular-Weight Heparin","Venous Thromboembolism","Cancer-Associated Thrombosis","Hematologic Malignancies","Direct Oral Anticoagulants","2025-12-18",{"date":167,"type":41},"2025-12-26",{"date":169,"type":41},"2024-11-22",{"date":171,"type":21},"2026-12-31",{"name":173,"class":48},"Medical University of Gdansk",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":181,"minAge":18,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":186,"conditions":187,"keywords":192,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":49},"100579990","phase-1-excretion-of-rivaroxaban-in-human-breast-milk-100579990","NCT06831474","Excretion of Rivaroxaban in Human Breast Milk","LACT","Inclusion Criteria:\n\n1. Postpartum within 6 weeks of delivery\n2. Greater than 18 years old at expected date of delivery\n3. English speaking\n4. Hemodynamically stable without concern for ongoing blood loss\n5. Non-breastfeeding\n6. Or breastfeeding an infant born at or equal to 37 weeks' gestation, weighing \\>2600g at birth and is not requiring intensive care\n7. Meet inclusion criteria for prophylactic rivaroxaban dose: pre-pregnancy BMI \\>\u002F= 40 and\u002For any personal history of VTE. Or \\>\u002F= 2 of the following: pre-pregnancy BMI 30-39, immobility, pregnancy complications, cesarean delivery, hysterectomy\n8. Or meet inclusion criteria for therapeutic rivaroxaban dose: have an indication for therapeutic anticoagulation per the American College of Obstetricians and Gynecologists' (ACOG) practice bulletin #196, or other indication per their primary team, and recommended for such anticoagulation per their primary practitioner.\n\nExclusion Criteria:\n\n1. Pregnant\n2. Less than 18 years old at estimated date of delivery\n3. Hemodynamic instability and\u002For concern for ongoing blood loss\n4. Newly diagnosed deep vein thrombosis (DVT) or pulmonary embolism (PE) in the postpartum period\n5. Abnormal maternal renal or liver function (creatinine clearance \\\u003C 30 mL\u002Fmin and\u002For liver function tests greater than lab normal)\n6. A contraindication to rivaroxaban: hypersensitivity to rivaroxaban; active pathological bleeding\n7. Breastfeeding an infant admitted to neonatal intensive care unit, infant gestational age at birth \\\u003C37w0d or weighing \\\u003C2600g.\n8. If all of the following are met: age less than 40, ambulating, body mass index (BMI) less than 30, no active history of malignancy.\n9. If patient lacks indication for therapeutic anticoagulation in the postpartum period per the American College of Obstetricians and Gynecologists' (ACOG) practice bulletin #196","FEMALE",{"count":183,"type":21},10,[185],"PHASE1","The purpose of this study is to investigate the distribution of rivaroxaban into human milk at both therapeutic and prophylactic doses, and over time with repeated dosing.",[188,189,29,159,190,191],"Postpartum","VTE Prophylaxis","Breastfeeding","Breast Milk Collection",[159,193,179,194],"Relative infant dose","Rivaroxaban in breast milk","2025-07-14",{"date":197,"type":41},"2025-07-17",{"date":199,"type":21},"2025-07",{"date":201,"type":21},"2026-07-31",{"name":203,"class":48},"Thomas Jefferson University",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":36,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":49},"100572396","padua-prediction-score-for-vte-risk-in-thoracic-surgery-patients-100572396","NCT06732726","Padua Prediction Score for VTE Risk in Thoracic Surgery Patients","Assessment of the Padua Prediction Score for Venous Thromboembolism Risk Stratification in Thoracic Surgery Patients: Insights From a Single-Center Cohort Study in Iraq","Inclusion Criteria:\n\n* Patients who have undergone preoperative Padua Prediction Score assessment.\n* Inpatients with a hospital stay over 3 days\n* Written informed consent obtained from patients or their legal guardians.\n* Availability for postoperative follow-up to assess outcomes like LEVT development or related complications.\n\nExclusion Criteria:\n\n* Preexisting LEVT or pulmonary embolism.\n* Severe Coagulopathy: Patients with inherited or acquired bleeding disorders (e.g., hemophilia, advanced liver disease).\n* receiving any anticoagulation therapy for any reason.\n* patients who did not undergo a postoperative D-dimer test.\n* Incomplete Data: missing essential clinical or laboratory data.\n* Pregnancy: pregnant women or those within six weeks postpartum.\n* Noncompliance: Patients unwilling or unable to adhere to study follow-up protocols.",{"count":60,"type":21},"The goal of this observational study is to assess the predictive accuracy of the Padua Prediction Score (PPS) for venous thromboembolism (VTE) risk in thoracic surgery patients.\n\nThe study aims to answer the following question:\n\nDoes the PPS provide a more accurate prediction of VTE risk?\n\nParticipants will:\n\nHave their VTE risk assessed using the PPS during their hospital admission.",[214,29],"DVT - Deep Vein Thrombosis",[216],"Padua Prediction Score (PPS)","2025-03-16",{"date":219,"type":41},"2025-03-18",{"date":221,"type":21},"2025-04-20",{"date":223,"type":21},"2025-07-15",{"name":225,"class":48},"Al-Nahrain University",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":234,"conditions":235,"keywords":236,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":49},"100573664","aqt90-flex-d-dimer-clinical-sensitivity-and-specificity-100573664","NCT06749223","AQT90 FLEX D-dimer Clinical Sensitivity and Specificity","Inclusion Criteria:\n\n* Subject is 18 years of age and older\n* Subject, who presents with signs and symptoms of VTE and had low or moderate pre-test probability of DVT or PE assessed by Well's score\n* Subject must be able to understand information given, and be willing and able to voluntarily give their consent to participate in this study\n\nExclusion Criteria:\n\n* Subject, who is pregnant\n* Subject, who has received fibrinolytic therapy within the previous seven days\n* Subject, who has received treatment with anticoagulants (unfractionated heparin, LMWH, VKA (vitamin K-antagonists), DOACs (direct oral anticoagulants) within the previous seven days\n* Subject, who has had trauma or surgery within the previous four weeks\n* Subject with malignancy\n* Subject with disseminated intravascular coagulation (DIC)\n* Subject, who has an invalid written informed consent or has withdrawn consent",{"count":233,"type":21},600,"The goal of this study is evaluate the clinical performance of the AQT90 FLEX D-dimer Test as an aid in the diagnosis of Venous Thromboembolism.",[29],[237],"D-dimer","2025-02-13",{"date":240,"type":41},"2025-02-17",{"date":242,"type":41},"2022-04-04",{"date":244,"type":21},"2025-06-30",{"name":246,"class":247},"Radiometer Medical ApS","INDUSTRY",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":22,"phases":256,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":4},"100560913","a-multicenter-open-label-non-inferiority-randomized-controlled-trial-of-postoperative-vte-prevention-in-chinese-patients-after-colorectal-cancer-surgery-100560913","NCT06583330","A Multicenter, Open-Label, Non-Inferiority Randomized Controlled Trial of Postoperative VTE Prevention in Chinese Patients After Colorectal Cancer Surgery","Inclusion Criteria:\n\n* Age\\>18 years old; Diagnosed with colorectal cancer and undergoing curative, palliative, or other limited surgeries (laparoscopic or open surgery), with an estimated surgery time of\\>45 minutes; Expected postoperative survival\\>6 months; Expected Caprini score of ≥ 5 on the first day after surgery; The patient agrees to the research plan and signs an informed consent form.\n\nExclusion Criteria:\n\n* Renal dysfunction (CrCl\\<30 mL\u002Fmin) or liver dysfunction (ALT\\>3 times the upper limit of normal); Known allergies to LMWH, anesthetics, or contrast agents; There is a systemic bleeding disorder or bleeding tendency, such as active peptic ulcer, uncontrolled hypertension, cerebral thrombosis within 6 months, cerebral hemorrhage, or a history of neurosurgical surgery; Known brain metastases, endocarditis, or previous heparin induced thrombocytopenia; VTE occurred within 3 months before surgery; Use heparin or oral anticoagulant therapy within 5 days before surgery; Pregnant or lactating women; Pregnant or lactating women; Any conditions that researcher determines the subject not suitable for anticoagulant therapy.",{"count":255,"type":21},1448,[24],"research objective\n\n1. Optimize VTE prevention management after CRC surgery.\n2. Improve the prevention and treatment level of VTE in current perioperative patients.\n3. Reduce the social burden of VTE related diseases.\n\nParticipants will:\n\n1. start low molecular weight heparin prophylaxis within 24 hours post-surgery.\n2. The prophylactic regimen for the experimental group lasted 14 days, while the control group received it for 28 days. Low molecular weight heparin is given subcutaneously at a dose of 0.3ml once daily.\n3. atients underwent lower limb color Doppler ultrasound on postoperative days 7 ± 2, 14 ± 3, and 28 ± 5, which included screening for thrombosis in the proximal deep veins (femoral, popliteal), distal deep veins (posterior tibial, fibular, and muscular veins), and their perforating branches.",[259,29],"Colorectal Surgery","2024-09-01",{"date":262,"type":41},"2024-09-04",{"date":264,"type":21},"2024-10",{"date":266,"type":21},"2027-03",{"name":268,"class":48},"Beijing Friendship Hospital"]